This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 4441299 results found since Jan 2013.

Ultrasound-based radiomic analysis of the peripheral nerves for differentiation between CIDP and POEMS syndrome
CONCLUSION: US-based radiomic analysis has high AUC values in differentiating POEM syndrome from CIDP. Machine-learning algorithms further improved the discriminative ability.PMID:37376758 | DOI:10.1177/02841851231181680
Source: Acta Radiologica - June 28, 2023 Category: Radiology Authors: Jun Hashiba Hajime Yokota Kota Abe Yukari Sekiguchi Shinobu Ikeda Atsuhiko Sugiyama Satoshi Kuwabara Takashi Uno Source Type: research

Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP
Abstract To investigate the use of nerve ultrasound (NUS) along with the European Federation of Neurological Societies (EFNS) guidelines and clinical scores in untreated, recently diagnosed chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) vs. long-lasting treated CIDP. NUS and nerve conduction studies (NCS) of predefined nerves/cervical roots were performed in CIDP on diagnostic onset and “chronic-CIDP” (diagnosis and therapy >6 months), compared to controls. Nerve morphology was quantified using the modified ultrasound pattern sum score mUPSS, which is the sum of 3 ultrasound scores derive...
Source: Journal of Neurology - March 25, 2016 Category: Neurology Source Type: research

Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
CONCLUSIONS: We cannot be certain based on available evidence whether daily oral prednisone improves impairment compared to no treatment. However, corticosteroids are commonly used, based on widespread availability, low cost, very low-quality evidence from observational studies, and clinical experience. The weakness of the evidence does not necessarily mean that corticosteroids are ineffective. High-dose monthly oral dexamethasone for six months is probably no more or less effective than daily oral prednisolone. Plasma exchange produces short-term improvement in impairment as determined by neurological examination, and pro...
Source: Cochrane Database of Systematic Reviews - January 12, 2017 Category: Journals (General) Authors: Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH Tags: Cochrane Database Syst Rev Source Type: research

Treatment Approaches for Atypical CIDP
The variants of chronic inflammatory demyelinating polyneuropathy (CIDP) differ not just in their clinical, pathological and electrophysiological characteristics, but often in their indifferent response to conventional immunosuppressive agents which are effective in typical CIDP. High quality evidence is lacking as far as the management of these atypical variants is concerned. In this review, we summarize the treatment approaches to each of these CIDP variants based on existing data. Distal acquired demyelinating symmetric polyneuropathy (DADS) has the phenotype of a symmetric, demyelinating sensory, length-dependent polyn...
Source: Frontiers in Neurology - March 15, 2021 Category: Neurology Source Type: research

The neurophysiological lesson from the Italian CIDP database
ConclusionOur findingsdemonstrated that the diagnosis of CIDP may be missed due to inadequate or incomplete electrophysiological examination or interpretation. At the same time, thesedata taken together could be useful to draw a thoughtful electrophysiological approach to patients suspected of CIDP.
Source: Neurological Sciences - May 21, 2021 Category: Neurology Source Type: research

Patient Demographics and Health Plan Paid Costs in CIDP (PD1.007)
CONCLUSIONS: Annual health care costs for CIDP are substantial with a large cost burden in pharmacy utilization. IVIg (FDA approved for CIDP) is the primary cost driver. With the emphasis on the rational use of health care resources, studies are needed to determine optimal long-term treatment strategies for CIDP, particularly with regard to IVIg.Supported by: An American Brain Foundation - Myasthenia Gravis Foundation of America Clinician Scientist Development Award (Dr. Guptill).Disclosure: Dr. Guptill has received personal compensation for activities with UCB Pharma as a consultant. Dr. Bromberg has received personal com...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Guptill, J., Bromberg, M., Zhu, L., Sharma, B., Thompson, A., Krueger, A., Sanders, D. Tags: PD1 Peripheral Nerve Source Type: research

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sera Alter Regulators Of Schwann Cell Differentiation (P6.008)
Conclusions: Our data implicate that soluble serum factors in CIDP can influence regulators of SC differentiation which results in an altered SC phenotype. Preliminary experiments point to role of GM-CSF in this process. Further studies are ongoing to determine the functional consequences and the molecular pathways responsible for these changes.Disclosure: Dr. Joshi has nothing to disclose. Dr. Bobylev has nothing to disclose. Dr. Ritter has nothing to disclose. Dr. Heinen has nothing to disclose. Dr. Lehmann has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Joshi, A., Bobylev, I., Ritter, C., Heinen, A., Lehmann, H. Tags: General Neurology V Source Type: research

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Sera Alter Regulators Of Schwann Cell Differentiation (I6-1.010)
Conclusions: Our data implicate that soluble serum factors in CIDP can influence regulators of SC differentiation which results in an altered SC phenotype. Preliminary experiments point to role of GM-CSF in this process. Further studies are ongoing to determine the functional consequences and the molecular pathways responsible for these changes.Disclosure: Dr. Joshi has nothing to disclose. Dr. Bobylev has nothing to disclose. Dr. Ritter has nothing to disclose. Dr. Heinen has nothing to disclose. Dr. Lehmann has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Joshi, A., Bobylev, I., Ritter, C., Heinen, A., Lehmann, H. Tags: Peripheral Neuropathies Poster Presentations Source Type: research

Nerve pathologic features differentiate POEMS syndrome from CIDP (S42.004)
CONCLUSIONS: Nerve biopsies can be helpful distinguishing POEMS syndrome from CIDP with POEMS syndrome showing a higher degree of axonal degeneration and more epineurial neovascularization whereas CIDP shows more endoneurial inflammation and more onion-bulbs. These findings suggest that the underlying mechanisms in these conditions are different with POEMS having vasculopathy (associated with elevated VEGF levels) and CIDP is inflammatory demyelination.Disclosure: Dr. Piccione has nothing to disclose. Dr. Engelstad has nothing to disclose. Dr. Mauermann has nothing to disclose. Dr. Dispenzieri has nothing to disclose. Dr. ...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Piccione, E., Engelstad, J., Mauermann, M., Dispenzieri, A., Dyck, P. J. B. Tags: New Developments in Peripheral Neuropathies Source Type: research

CIDP diagnostic pitfalls and perception of treatment benefit
Conclusions: CIDP misdiagnosis is common. Over-reliance on subjective patient-reported perception of treatment benefit, liberal electrophysiologic interpretation of demyelination, and placing an overstated importance on mild or moderate cytoalbuminologic dissociation are common diagnostic errors. Utilization of clear and objective indicators of treatment efficacy might improve our ability to make informed treatment decisions.
Source: Neurology - August 10, 2015 Category: Neurology Authors: Allen, J. A., Lewis, R. A. Tags: Autoimmune diseases, All Neuromuscular Disease, Chronic inflammatory demyelinating polyneuropathy, EMG ARTICLE Source Type: research

Diffusion Tensor Imaging as a Functional Measure in Determination of Peripheral Nerve Lesions in CIDP Treated with Subcutaneous Immunoglobulin (P4.078)
Conclusions: We found decreased FA- and increased ADC-values on DTI of sciatic and tibial nerves in CIDP versus controls suggesting that in CIDP demyelination can be detected by MRI. Study support: Octapharma PharmaceuticalsDisclosure: Dr. Jakobsen has nothing to disclose. Dr. Væggemose has nothing to disclose. Dr. Henning has received research support from Octapharma Pharmaceuticals. Dr. Markvardsen has received research support from Octapharma Pharmaceuticals.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Jakobsen, J., Vaeggemose, M., Andersen, H., Markvardsen, L. Tags: MRI and Ultrasonography Studies in Peripheral Neuropathies Source Type: research